Company: REVB
Filing Date: 2025-05-20
Form Type: S-1
Source: 0001213900-25-045828
Chunk: 212

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-05-20
Form: S-1
Chunk 212
---
 Class B
Common Stock Warrants were estimated using the Black-Scholes option pricing model with the following assumptions:

| Volatility              |     |  144 | % |
| Expected term (years)   |     |    5 |   |
| Risk-free interest rate |     | 2.69 | % |
| Expected dividend yield |     |  0.0 | % |

F-21 REVELATION BIOSCIENCES, INC.
Notes to the Consolidated Financial Statements 10. Warrants(cont.)

Class B Placement Agent Common Stock Warrants

In connection with the July 2022
Public Offering, the Company issued warrants to the Placement Agent to purchase up to shares of common stock at an exercise price of
$ per share (the “Class B Placement Agent Common Stock Warrants”), valued on the public offering purchase date
in the aggregate at $ million and included in the issuance costs of the public offering and treated as equity. The warrants were
exercisable immediately upon issuance, provide for a cash or cashless exercise right and expire on .

The fair value of the Class B
Placement Agent Common Stock Warrants were estimated using the Black-Scholes option pricing model with the following assumptions:

| Volatility              |     |  144 | % |
| Expected term (years)   |     |    5 |   |
| Risk-free interest rate |     | 2.69 | % |
| Expected dividend yield |     |  0.0 | % |

Class C Pre-Funded Warrants

In connection with the February 2023
Public Offering, the Company issued pre-funded warrants to purchase up to shares of common stock at an exercise price of $ per
share. Between February 14, 2023 and April 6, 2023, the Company received notices of cash exercise for the Class C Pre-Funded
Warrants issued in connection with the February 2023 Public Offering for shares of common stock at a total purchase price of
$. As of December 31, 2024, there were no Class C Pre-Funded Warrants outstanding.

Class C Common Stock Warrants

In connection with the February 2023
Public Offering, the Company issued Class C Common Stock Warrants to purchase up to shares of common stock at an
exercise price of $ per share, valued on the public offering purchase date in the aggregate at $ and included in the
issuance costs of the public offering and treated as a liability. The warrants were